28 completed, 16 recruiting, 10 terminated, 10 unknown. 73 Phase 1, 21 Phase 2.
Follow B-cell Lymphoma: new trials by email Literature Review of B-cell Lymphoma trials Research Report on B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-03 |
| Phase I Study of FXS0683 in the Treatment of Blood Tumors FXS0683 - B-Cell Lymphoma, Acute Myeloid Leukemia | Phase 1 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 228 | 2026-06-02 | 2026-10-14 |
| In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma SL1617 Injection - B-cell Lymphoma | Phase 1 | Recruiting | Chinese PLA General Hospital | 18 | 2026-06-01 | 2026-08-20 |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) LY4152199 - IV - Lymphoma, Non-Hodgkin, B-cell Lymphoma | Phase 1 | Recruiting | Eli Lilly and Company | 215 | 2026-05-28 | 2026-11-04 |
| Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma BAFF-R CAR-T cells - B-cell Lymphoma | Phase 1 | Recruiting | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 30 | 2026-01-01 | 2026-02-27 |
| Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies CAR-T - Multiple Myeloma, B-cell Lymphoma | Phase 1 | Recruiting | The Third Affiliated Hospital of Southern Medical University | 60 | 2025-01-15 | 2025-01-06 |
| A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies XS-04 tablet - B-cell Lymphoma, Acute Myeloid Leukemia | Phase 1 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 168 | 2025-01-14 | 2026-09-25 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma Triple-targeted CAR-T Therapy - B-cell Lymphoma | Phase 1 | Withdrawn | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2024-11-07 | 2026-05-06 | |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
| A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas ASP2802, MA-20 - B-cell Lymphoma | Phase 1 | Terminated | Astellas Pharma Global Development, Inc. | 1 | 2024-09-06 | 2025-10-28 |
| CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) CAR20(NAP)-T, Cyclophosphamide, Fludarabine - B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Uppsala University | 18 | 2024-05-01 | 2026-11-10 |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas Tazemetostat Pill - Follicular Lymphoma, B-Cell Lymphoma | Phase 1 | Active not recruiting | Weill Medical College of Cornell University | 15 | 2023-10-04 | 2026-06-17 |
| IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas IKS03 - B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Iksuda Therapeutics Ltd. | 140 | 2023-09-05 | 2026-11-03 |
| A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 60 | 2023-07-01 | 2023-07-11 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies CTX112 - B-cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 120 | 2023-03-10 | 2025-11-14 |
| Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma 19(T2)28z1xx TRAC T cell - B-Cell Lymphoma, Large B-cell Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-02-23 | 2026-04-22 |
| Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies Etoposide, Doxorubicin, Cyclophosphamide - B-cell Lymphoma, Burkitt Lymphoma | Phase 1 | Active not recruiting | Medical College of Wisconsin | 11 | 2023-01-26 | 2026-10-14 |
| ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies Cyclophosphamide, Fludarabine, ACE1831 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Completed | Acepodia Biotech, Inc. | 16 | 2023-01-21 | 2026-06-30 |
Showing 20 of 73. Sign in to see all of them.
Lymphoma, B-Cell (73) · Lymphoma, Non-Hodgkin (21) · Lymphoma, Mantle-Cell (16) · Lymphoma (15) · Lymphoma, Follicular (15) · Burkitt Lymphoma (12) · Lymphoma, B-Cell, Marginal Zone (12) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Leukemia, B-Cell (10) · Lymphoma, Large B-Cell, Diffuse (10) · Recurrence (8) · Waldenstrom Macroglobulinemia (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Multiple Myeloma (5) · Leukemia, Myeloid, Acute (4)
Hemic and Lymphatic Diseases (73) · Immune System Diseases (73) · Immunoproliferative Disorders (73) · Lymphatic Diseases (73) · Lymphoproliferative Disorders (73) · Neoplasms by Histologic Type (73) · Neoplasms (70) · Lymphoma (58) · Lymphoma, Non-Hodgkin (52) · Hematologic Diseases (30) · Leukemia (24) · Leukemia, Lymphoid (21) · Pathologic Processes (20) · Pathological Conditions, Signs and Symptoms (20) · Disease Attributes (18)
Rituximab (13) · Cyclophosphamide (11) · fludarabine (9) · obinutuzumab (7) · Etoposide (4) · venetoclax (4) · Gemcitabine (3) · Interleukin-2 (3) · Prednisone (3) · glofitamab (3) · ibrutinib (3) · Acetaminophen (2) · Bendamustine Hydrochloride (2) · Cytarabine (2) · Dexamethasone (2)
National Cancer Institute (NCI) (3) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (2) · CRISPR Therapeutics AG (2) · Eli Lilly and Company (2) · Hoffmann-La Roche (2) · M.D. Anderson Cancer Center (2) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2) · TG Therapeutics, Inc. (2) · The Lymphoma Academic Research Organisation (2) · AbbVie (1) · Acepodia Biotech, Inc. (1) · Acrotech Biopharma Inc. (1) · Agenus Inc. (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1)
United States (38) · China (24) · Australia (11) · France (8) · Italy (8) · Germany (6) · Spain (6) · Canada (5) · Poland (5) · United Kingdom (5) · South Korea (4) · Belgium (3) · Sweden (3) · Denmark (2) · Hong Kong (2)
Abraham Leung, MD (1) · Andrew Davies, Prof (1) · Annie Weaver, PhD (1) · Arturo Molina, MD (1) · Baijun Fang, Prof. (1) · Caitlin K Gribbin, M.D. (1) · Carlos Ramos, MD (1) · David Marin, MD (1)
PMID 23045577, PMID 23295790, PMID 25381051, PMID 26193343, PMID 26966027, PMID 27482888, PMID 31011207, PMID 33676628, PMID 34398557, PMID 34464155, PMID 34687939, PMID 34780125, PMID 34889384, PMID 35383885, PMID 35432352, PMID 35488407, PMID 35595730, PMID 35605184, PMID 35798714, PMID 35900694, PMID 36059523, PMID 36477110, PMID 37192437, PMID 37407001, PMID 37486616, PMID 37624619, PMID 37774014, PMID 37883795, PMID 38376944, PMID 38502198, PMID 38598516, PMID 38861666, PMID 39033770, PMID 39415923, PMID 40000354, PMID 40610174, PMID 40749164, PMID 40845254, PMID 41055698, PMID 41144785, PMID 41544219, PMID 42069409, PMID 42085626, PMID 42248607, PMID 42496861, PMID 42786239, PMID 42789493
2017 (2), 2005 (1), 2015 (1), 2018 (1), 2025 (1), R01CA141303 (1)